Hydroxyapatite-biopolymers-ZnO composite with sustained Ceftriaxone release as a drainage system for treatment of purulent cavities

Composite based on nano-sized hydroxyapatite (HA), zinc oxide (ZnO), chitosan (CS), alginate (Alg) with the function of sustained Ceftriaxone (CF) release was created as molecular sorption-aspiration drainage system (SADS), designed for the treatment of purulent cavities of various genesis, including peritonitis. ZnO stabilizes the composite structurally, reducing the swelling by 1.5 and porosity by 1.4 times. The absorption of tryptophan (Trp) by SADS for 72 h from aqueous solution is 80%, while from PBS - 50%. The content of ZnO (15,20%) slows the CF release by 1.6 times on the first day of SADS installation and reduces the likelihood of “burst” drug release. CF release exponent of ZnO-containing composites indicates the non-Fickian diffusion kinetics. 20%ZnO-containing composite is closest to zero-order kinetics. The reduction of the concentration of E. coli microbial cells for 43% in the presence of HA-nZnO-Alg/CS -based CADS and positive therapeutic pathomorphosis were observed in vivo. [Display omitted] •Hydroxyapatite-biopolymers-ZnO composite as a sorption-aspiration drainage system (SADS) created•ZnO stabilizes the composite structurally, reducing swelling and porosity by 1.5 and 1.4 times.•ZnO slows the Ceftriaxone release by 1.6 and reduces the likelihood of “burst” drug release.•SADS absorbs 80% of tryptophan amino acid from aqueous solution and 50% from PBS for 72 h.•SADS reduces the E. coli content in the intestinal cavity of animals with peritonitis by 43%.